Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma

Eric Jonasch, Christopher G. Wood, Surena F. Matin, Shi Ming Tu, Lance C. Pagliaro, Paul G. Corn, Ana Aparicio, Pheroze Tamboli, Randall E. Millikan, Xuemei Wang, John C. Araujo, Wadih Arap, Nizar Tannir

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Purpose: To assess safety and efficacy of presurgical bevacizumab in patients with metastatic renal cell carcinoma (mRCC), and to explore the hypothesis that pretreatment of patients with antiangiogenic therapy will select patients who benefit most from cytoreductive nephrectomy. Patients and Methods: Patients with newly diagnosed, clear cell mRCC whose primary tumors were considered resectable were enrolled. In this single-arm, phase II trial, patients received bevacizumab plus erlotinib (first patients, n = 23) or bevacizumab alone (n = 27 patients) for 8 weeks followed by restaging. If patients demonstrated progressive disease and had declining performance statuses after 8 weeks, nephrectomy procedures were deferred. Postoperatively, patients continued on the study drug or drugs if disease stabilization or regression had occurred. Results: Between March 2005 and March 2008, 52 patients were enrolled on study, and 50 were included in the analysis. By Memorial Sloan-Kettering Cancer Center criteria, 82% of patients had intermediate-risk, and 18% had poor-risk, features. Forty-two patients underwent nephrectomy. Median progression-free survival was 11.0 months (95% CI, 5.5 to 15.6 months). Median overall survival was 25.4 months (95% CI, 11.4 months to not estimable). Two perioperative deaths occurred; neither was attributable to study drug. Wound dehiscence resulted in treatment discontinuation for three patients and treatment delay for two others. Conclusion: Presurgical treatment with bevacizumab therapy yields clinical outcomes comparable to postsurgical treatment with antiangiogenic therapy in patients with mRCC, but it may result in wound-healing delays. Prospective, randomized trials to test the use of presurgical therapy as a method to select appropriate patients for cytoreductive nephrectomy are warranted.

Original languageEnglish (US)
Pages (from-to)4076-4081
Number of pages6
JournalJournal of Clinical Oncology
Volume27
Issue number25
DOIs
StatePublished - Sep 1 2009
Externally publishedYes

Fingerprint

Feasibility Studies
Renal Cell Carcinoma
Nephrectomy
Bevacizumab
Therapeutics
Pharmaceutical Preparations
Wound Healing
Disease-Free Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jonasch, E., Wood, C. G., Matin, S. F., Tu, S. M., Pagliaro, L. C., Corn, P. G., ... Tannir, N. (2009). Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 27(25), 4076-4081. https://doi.org/10.1200/JCO.2008.21.3660

Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. / Jonasch, Eric; Wood, Christopher G.; Matin, Surena F.; Tu, Shi Ming; Pagliaro, Lance C.; Corn, Paul G.; Aparicio, Ana; Tamboli, Pheroze; Millikan, Randall E.; Wang, Xuemei; Araujo, John C.; Arap, Wadih; Tannir, Nizar.

In: Journal of Clinical Oncology, Vol. 27, No. 25, 01.09.2009, p. 4076-4081.

Research output: Contribution to journalArticle

Jonasch, E, Wood, CG, Matin, SF, Tu, SM, Pagliaro, LC, Corn, PG, Aparicio, A, Tamboli, P, Millikan, RE, Wang, X, Araujo, JC, Arap, W & Tannir, N 2009, 'Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma', Journal of Clinical Oncology, vol. 27, no. 25, pp. 4076-4081. https://doi.org/10.1200/JCO.2008.21.3660
Jonasch, Eric ; Wood, Christopher G. ; Matin, Surena F. ; Tu, Shi Ming ; Pagliaro, Lance C. ; Corn, Paul G. ; Aparicio, Ana ; Tamboli, Pheroze ; Millikan, Randall E. ; Wang, Xuemei ; Araujo, John C. ; Arap, Wadih ; Tannir, Nizar. / Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 25. pp. 4076-4081.
@article{5c5c9ed6a06d4947a0ff2ed7dd7ac9e5,
title = "Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma",
abstract = "Purpose: To assess safety and efficacy of presurgical bevacizumab in patients with metastatic renal cell carcinoma (mRCC), and to explore the hypothesis that pretreatment of patients with antiangiogenic therapy will select patients who benefit most from cytoreductive nephrectomy. Patients and Methods: Patients with newly diagnosed, clear cell mRCC whose primary tumors were considered resectable were enrolled. In this single-arm, phase II trial, patients received bevacizumab plus erlotinib (first patients, n = 23) or bevacizumab alone (n = 27 patients) for 8 weeks followed by restaging. If patients demonstrated progressive disease and had declining performance statuses after 8 weeks, nephrectomy procedures were deferred. Postoperatively, patients continued on the study drug or drugs if disease stabilization or regression had occurred. Results: Between March 2005 and March 2008, 52 patients were enrolled on study, and 50 were included in the analysis. By Memorial Sloan-Kettering Cancer Center criteria, 82{\%} of patients had intermediate-risk, and 18{\%} had poor-risk, features. Forty-two patients underwent nephrectomy. Median progression-free survival was 11.0 months (95{\%} CI, 5.5 to 15.6 months). Median overall survival was 25.4 months (95{\%} CI, 11.4 months to not estimable). Two perioperative deaths occurred; neither was attributable to study drug. Wound dehiscence resulted in treatment discontinuation for three patients and treatment delay for two others. Conclusion: Presurgical treatment with bevacizumab therapy yields clinical outcomes comparable to postsurgical treatment with antiangiogenic therapy in patients with mRCC, but it may result in wound-healing delays. Prospective, randomized trials to test the use of presurgical therapy as a method to select appropriate patients for cytoreductive nephrectomy are warranted.",
author = "Eric Jonasch and Wood, {Christopher G.} and Matin, {Surena F.} and Tu, {Shi Ming} and Pagliaro, {Lance C.} and Corn, {Paul G.} and Ana Aparicio and Pheroze Tamboli and Millikan, {Randall E.} and Xuemei Wang and Araujo, {John C.} and Wadih Arap and Nizar Tannir",
year = "2009",
month = "9",
day = "1",
doi = "10.1200/JCO.2008.21.3660",
language = "English (US)",
volume = "27",
pages = "4076--4081",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "25",

}

TY - JOUR

T1 - Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma

AU - Jonasch, Eric

AU - Wood, Christopher G.

AU - Matin, Surena F.

AU - Tu, Shi Ming

AU - Pagliaro, Lance C.

AU - Corn, Paul G.

AU - Aparicio, Ana

AU - Tamboli, Pheroze

AU - Millikan, Randall E.

AU - Wang, Xuemei

AU - Araujo, John C.

AU - Arap, Wadih

AU - Tannir, Nizar

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Purpose: To assess safety and efficacy of presurgical bevacizumab in patients with metastatic renal cell carcinoma (mRCC), and to explore the hypothesis that pretreatment of patients with antiangiogenic therapy will select patients who benefit most from cytoreductive nephrectomy. Patients and Methods: Patients with newly diagnosed, clear cell mRCC whose primary tumors were considered resectable were enrolled. In this single-arm, phase II trial, patients received bevacizumab plus erlotinib (first patients, n = 23) or bevacizumab alone (n = 27 patients) for 8 weeks followed by restaging. If patients demonstrated progressive disease and had declining performance statuses after 8 weeks, nephrectomy procedures were deferred. Postoperatively, patients continued on the study drug or drugs if disease stabilization or regression had occurred. Results: Between March 2005 and March 2008, 52 patients were enrolled on study, and 50 were included in the analysis. By Memorial Sloan-Kettering Cancer Center criteria, 82% of patients had intermediate-risk, and 18% had poor-risk, features. Forty-two patients underwent nephrectomy. Median progression-free survival was 11.0 months (95% CI, 5.5 to 15.6 months). Median overall survival was 25.4 months (95% CI, 11.4 months to not estimable). Two perioperative deaths occurred; neither was attributable to study drug. Wound dehiscence resulted in treatment discontinuation for three patients and treatment delay for two others. Conclusion: Presurgical treatment with bevacizumab therapy yields clinical outcomes comparable to postsurgical treatment with antiangiogenic therapy in patients with mRCC, but it may result in wound-healing delays. Prospective, randomized trials to test the use of presurgical therapy as a method to select appropriate patients for cytoreductive nephrectomy are warranted.

AB - Purpose: To assess safety and efficacy of presurgical bevacizumab in patients with metastatic renal cell carcinoma (mRCC), and to explore the hypothesis that pretreatment of patients with antiangiogenic therapy will select patients who benefit most from cytoreductive nephrectomy. Patients and Methods: Patients with newly diagnosed, clear cell mRCC whose primary tumors were considered resectable were enrolled. In this single-arm, phase II trial, patients received bevacizumab plus erlotinib (first patients, n = 23) or bevacizumab alone (n = 27 patients) for 8 weeks followed by restaging. If patients demonstrated progressive disease and had declining performance statuses after 8 weeks, nephrectomy procedures were deferred. Postoperatively, patients continued on the study drug or drugs if disease stabilization or regression had occurred. Results: Between March 2005 and March 2008, 52 patients were enrolled on study, and 50 were included in the analysis. By Memorial Sloan-Kettering Cancer Center criteria, 82% of patients had intermediate-risk, and 18% had poor-risk, features. Forty-two patients underwent nephrectomy. Median progression-free survival was 11.0 months (95% CI, 5.5 to 15.6 months). Median overall survival was 25.4 months (95% CI, 11.4 months to not estimable). Two perioperative deaths occurred; neither was attributable to study drug. Wound dehiscence resulted in treatment discontinuation for three patients and treatment delay for two others. Conclusion: Presurgical treatment with bevacizumab therapy yields clinical outcomes comparable to postsurgical treatment with antiangiogenic therapy in patients with mRCC, but it may result in wound-healing delays. Prospective, randomized trials to test the use of presurgical therapy as a method to select appropriate patients for cytoreductive nephrectomy are warranted.

UR - http://www.scopus.com/inward/record.url?scp=70249115638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70249115638&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.21.3660

DO - 10.1200/JCO.2008.21.3660

M3 - Article

VL - 27

SP - 4076

EP - 4081

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 25

ER -